摘要
雷美替胺(ramelteon)通过选择性激动褪黑激素MT1和MT2受体,用于治疗难以入睡型失眠症。研究表明:其能有效地缩短入睡时间,提高总睡眠时间和入睡效率,且使用安全,无严重药物不良反应,长期用药不会产生滥用或药物依赖性。现对该药的药理学、药效学及临床应用等进行综述。
Ramelteon（ Rozerem^TM） is a selective MT1/MT2 receptor agonist and is the first drug in a new class of insomnia therapies. Ramelteon has demonstrated efficacy in the management of insomnia in terms of sleep latency, total sleep time and sleep efficiency. Rameheon is generally well tolerated and has low incidence of advance events with non-potential for abuse or dependence. This review summarizes the pharmacology, pharmacodynamics and clinical evaluation of ramelteon in the treatment of patients with insomnia.
出处
《中国新药杂志》
CAS
CSCD
北大核心
2006年第15期1309-1312,共4页
Chinese Journal of New Drugs
